Business Wire

ZEDRA

19.7.2022 10:02:06 CEST | Business Wire | Press release

Share
ZEDRA Boosts Its Global Offering With the Launch Of Pensions & Incentives

ZEDRA, the fast-growing international specialist in Active Wealth, Corporate & Global Expansion, and Fund solutions, today announces that the firm is launching a new pensions-focused offering – Pensions & Incentives.

The launch follows several recent acquisitions in the UK pension services space by ZEDRA, including Inside Pensions, a leading independent occupational pension scheme governance support provider PTL, a leading independent Pension Trustee and Governance services provider, both in 2021; and most recently, Caledonian Trustees Limited, a specialist provider of professional independent trustee and secretarial services to corporate pension and funeral plans. As the new offering goes live, PTL Limited has adopted the ZEDRA brand and become ZEDRA Governance Limited.

ZEDRA launches this offering as the UK pension trustee and governance services sector is undergoing significant changes and facing challenges that will require both dedicated effort and investment from long-term owners. As the regulatory system has become increasingly complex over recent years, so has the challenge of running a pension scheme for employers and trustees alike.

The number of pension schemes requiring support is expected to continue to grow for the foreseeable future, due to significantly increased regulatory and compliance burdens, a focus on end game strategies which benefit from professional trustee knowledge and understanding, and a lack of available company or member nominated trustees. With its new Pensions & Incentives offering, ZEDRA is expanding its services to meet these needs.

By entering the pension services industry now, ZEDRA strengthens its 20 years of presence in the employee incentive solutions and pension services space, providing global clients with employee benefits, trustee services, pensions and associated administrative solutions, through a dedicated team in Guernsey. Trustee services have always been at the heart of ZEDRA – the firm was founded in 2016 following the sale by Barclays of its -UK and offshore trust business to a group of private investors, including ZEDRA’s current Executive Chairman, Bart Deconinck.

ZEDRA Pensions & Incentives Services will consist of six offices in London, Reading, Leeds, Birmingham, St Albans and Guernsey and is made up of approximately 80 specialists with plans to further expand the team with acquisitions in the near future in the UK and Europe.

Ivo Hemelraad, ZEDRA Chief Executive Officer , said: “We are delighted to further expand our service offering by boosting our presence in the UK pension space. The journey we started with the acquisition of Interben Trustees Limited in 2019 followed by Inside Pensions, PTL and more recently, Caledonian Trustees, brings us to a market leading position for outsourced pension services in the UK pension space and abroad. Our dedicated teams with unrivalled expertise allow us to offer even greater service to those who are committed to providing the highest quality pension schemes available.”

ENDS

Notes to Editors
For more information, please contact:

Greentarget
Jamie Brownlee / Tom Engleback / Eleonore Basle / Sebastian Merrett
+44 203 963 1893
zedra@greentarget.co.uk

About ZEDRA

Find out more at www.zedra.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release

Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye